Dr. Jon Isaacsohn has served as Chief Executive Officer of CinRx Pharma since co-founding the company in 2015 and serves as a member of the company’s Board of Directors. Jon also served as founding Chief Executive Officer of a CinRx portfolio company, CinCor Pharma. He continues to serve as the Chief Executive Officer of CinRx’s other portfolio companies, including CinDome, CinSano, and CinFina. Prior to co-founding CinRx Pharma in 2015, Dr. Isaacsohn served as Chief Medical Officer for Teva Pharmaceuticals where he was responsible for developing Teva’s Specialty Drugs and overseeing the New Therapeutic Entities (NTEs) initiative across all therapeutic areas. He was Executive Vice President, Head of Medical & Regulatory Affairs at Medpace, a global leader in research-based drug development for nearly 15 years. Jon was a co-founder of the Metabolic & Atherosclerosis Research Center in Cincinnati, OH. During his career, Dr. Isaacsohn has been involved in developing numerous drugs from early phases through global submissions in various therapeutic areas. He trained in Internal Medicine and Cardiology at Harvard Medical School and was a member of the cardiology faculty at Yale Medical School.